Teva Inks Patent Deal With Collegium Over Painkiller

By Adam Lidgett (September 30, 2020, 10:04 PM EDT) -- Teva Pharmaceutical USA Inc. has inked a deal to resolve a patent case from Collegium Pharmaceutical Inc. over Teva's attempt to get a generic alternative to Collegium's Xtampza ER painkiller approved.

Collegium announced Wednesday that it had signed a settlement deal with Teva in a series of consolidated cases that focused on Teva's abbreviated new drug application, or ANDA, for a generic version of the drug.

Under the terms of the deal, Teva would be granted permission "to market its generic version of Xtampza ER in the United States beginning on or after Sept. 2, 2033," although the license is contingent...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!